We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

European Deep Brain Stimulation (DBS) Depression Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01331330
Recruitment Status : Completed
First Posted : April 8, 2011
Last Update Posted : May 19, 2015
Information provided by (Responsible Party):
Abbott Medical Devices

Brief Summary:
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for TR-MDD, single or recurrent episode on mood as measured by the MADRS.

Condition or disease Intervention/treatment Phase
Depressive Disorder, Major Device: Deep Brain Stimulation Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Clinical Evaluation of Different Device Parameters for the Management of Patients With Treatment Resistant Major Depressive Disorder, Single or Recurrent Episode, With Deep Brain Stimulation
Study Start Date : May 2011
Actual Primary Completion Date : December 2014
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Group B
Low Programming
Device: Deep Brain Stimulation
Low Programming
Other Name: Libra Deep Brain Stimulation System(St. Jude Medical Neuromodulation Division)

Experimental: Group A
Normal Programming
Device: Deep Brain Stimulation
Normal DBS Programming
Other Name: Libra Deep Brain Stimulation System (St. Jude Medical Neuromodulation Division)

Primary Outcome Measures :
  1. Percentage of change from mean baseline values in MADRS score [ Time Frame: 6 Months ]

Secondary Outcome Measures :
  1. Percentage of change from baseline value of HDRS [ Time Frame: 3, 6, 9, and 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women (non-pregnant) age is 21-70 years;
  • Diagnosed with non-psychotic major depressive disorder, single or recurrent episode by DSM-IV-TR criteria derived from the MINI;
  • First episode onset before age 45;
  • Current episode > 12 month duration;
  • In the current episode: Documented resistance to a minimum of 4 adequate depression treatments from at least 3 different categories;
  • In adult lifetime (>21 year of age) have experience a period of wellness as defined by DSM IV criteria;
  • MADRS score ≥22 at 2 separate baseline visits, rated by 2 separate psychiatrists;
  • GAF score <50;
  • Mini-mental state examination (MMSE) score >24;
  • No change in current antidepressant medication regimen or medication free for at least 4 weeks prior to study entry;
  • Able to give informed consent in accordance with institutional policies;

Exclusion Criteria:

  • A diagnosis of bipolar I or bipolar II disorder by DSM-IV-TR criteria, derived from the MINI;
  • Meets criteria for borderline or antisocial personality disorder in the last 12 months by DSM-IV-TR criteria, derived from the Cluster B Personality Disorders Sections 301.7 - 301.83, preferably screened via SCID-II at Baseline visit (optional);
  • In the current depressive episode, has been diagnosed with General Anxiety Disorder (GAD) - as defined by the DSM-IV-TR, and GAD is the primary diagnosis;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01331330

Layout table for location information
CHU Pasteur
Nice, France, 06002
Hôpital La Pitié Salpêtrière
Paris, France, 75651
Hadassah-Hebrew University Medical Center
Jerusalem, Israel, 91120
United Kingdom
King's College London
London, United Kingdom, SE5 9RS
National Hospital for Neurology and Neurosurgery - UCL
London, United Kingdom, WC1N 3
Sponsors and Collaborators
Abbott Medical Devices
Layout table for investigator information
Study Director: DeLea Peichel Abbott Medical Devices
Layout table for additonal information
Responsible Party: Abbott Medical Devices
ClinicalTrials.gov Identifier: NCT01331330    
Other Study ID Numbers: NM-09-035-EU-DB
First Posted: April 8, 2011    Key Record Dates
Last Update Posted: May 19, 2015
Last Verified: May 2015
Keywords provided by Abbott Medical Devices:
Depressive Disorder
Implantable Stimulation Electrodes
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms